scholarly journals Liver transplantation in a child with liver cirrhosis caused by langerhans cell histiocytosis: a case report

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Qi Wang ◽  
Shuguang Jin ◽  
Bo Xiang ◽  
Jing Chen

Abstract Background Langerhans cell histiocytosis (LCH) is a rare condition that has a variety of clinical manifestations. But LCH in children localized only in the hepatobiliary system is unusual. Case presentation. Here we reported a rare case of a 2-year-old boy who was serendipitously found to have elevated liver enzymes while undergoing treatment of a perianal abscess. After a period of earlier conservative treatment in another hospital, the perianal abscess had resolved but the levels of liver enzymes were still rising slowly. The child was then referred to our institution for a definitive diagnosis. After laboratory tests, imaging and pathological examinations, a diagnosis of liver cirrhosis and sclerosing cholangitis was established, although the cause was unclear. Subsequently, living-donor liver transplantation was performed due to deterioration in liver function. Following successful liver transplantation, a diagnosis of LCH localized only within the hepatobiliary system was finally confirmed, based on additional pathological and imaging investigation. Additionally, the BRAF V600E mutation in this patient was also confirmed. The child has now recovered without evidence of LCH recurrence. Conclusions LCH localized only within the hepatobiliary system is unusual. The presence of unexplainable sclerosing cholangitis and liver cirrhosis in any child should raise the suspicion of LCH.

2002 ◽  
Vol 38 (3) ◽  
pp. 178-182 ◽  
Author(s):  
Jorge Braier ◽  
Mirta Ciocca ◽  
Antonio Latella ◽  
Maria G. de Davila ◽  
Marina Drajer ◽  
...  

Medicine ◽  
2017 ◽  
Vol 96 (9) ◽  
pp. e5994 ◽  
Author(s):  
Yunhua Tang ◽  
Zhiheng Zhang ◽  
Maogen Chen ◽  
Weiqiang Ju ◽  
Dongping Wang ◽  
...  

2006 ◽  
Vol 44 (4) ◽  
pp. 829-831 ◽  
Author(s):  
William Griffiths ◽  
Susan Davies ◽  
Paul Gibbs ◽  
Andrew Thillainayagam ◽  
Graeme Alexander

Author(s):  
Nazneen A. Kader ◽  
Indusarath S. ◽  
N. K. Supriya

Liver is affected as a late complication of high risk cases of Langerhans cell histiocytosis. Sclerosing cholangitis is a rare pattern associated with Langerhans cell histiocytosis of liver, which is even rarer in the adult population and has high mortality. The treatment is difficult and may require liver transplantation. We report a unique case of a 40-year-old female who developed sclerosing cholangitis associated with Langerhans cell histiocytosis without any evidence of involvement of other systems. Our patient required only surgery, and had been followed up for two years without recurrence. We could not find any other case of solitary liver involvement of Langerhans cell histiocytosis in literature published so far.


Dermatology ◽  
2004 ◽  
Vol 209 (4) ◽  
pp. 335-337 ◽  
Author(s):  
Ruggero Caputo ◽  
Angelo V. Marzano ◽  
Emanuela Passoni ◽  
Luigi R. Fassati ◽  
Francesca Agnelli

2011 ◽  
Vol 11 (8) ◽  
pp. 1755-1756 ◽  
Author(s):  
R. J. Lee ◽  
C. Leung ◽  
E. J. Lim ◽  
P. W. Angus ◽  
P. S. Bhathal ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Shunqiao Feng ◽  
Lin Han ◽  
Mei Yue ◽  
Dixiao Zhong ◽  
Jing Cao ◽  
...  

Abstract Background Langerhans cell histiocytosis (LCH) is a rare neoplastic disease that occurs in both children and adults, and BRAF V600E is detected in up to 64% of the patients. Several studies have discussed the associations between BRAF V600E mutation and clinicopathological manifestations, but no clear conclusions have been drawn regarding the clinical significance of the mutation in pediatric patients. Results We retrieved the clinical information for 148 pediatric LCH patients and investigated the BRAF V600E mutation using next-generation sequencing alone or with droplet digital PCR. The overall positive rate of BRAF V600E was 60/148 (41%). The type of sample (peripheral blood and formalin-fixed paraffin-embedded tissue) used for testing was significantly associated with the BRAF V600E mutation status (p-value = 0.000 and 0.000). The risk of recurrence declined in patients who received targeted therapy (p-value = 0.006; hazard ratio 0.164, 95%CI: 0.046 to 0.583). However, no correlation was found between the BRAF V600E status and gender, age, stage, specific organ affected, TP53 mutation status, masses close to the lesion or recurrence. Conclusions This is the largest pediatric LCH study conducted with a Chinese population to date. BRAF V600E in LCH may occur less in East Asian populations than in other ethnic groups, regardless of age. Biopsy tissue is a more sensitive sample for BRAF mutation screening because not all of circulating DNA is tumoral. Approaches with low limit of detection or high sensitivity are recommended for mutation screening to avoid type I and II errors.


Sign in / Sign up

Export Citation Format

Share Document